|
The professionalism of Halsin towards investor and public relations is far beyond the norm, in particular your ‘can do’ service attitude."
OUR WORK - Case Studies
Background:
Addex Pharmaceuticals is developing a new class of therapeutics called allosteric modulators. This novel platform approach has generated a broad pipeline of products in multiple therapy areas. Their lead candidate, ADX10059, was scheduled to report clinical data in 3 indications leading up to the company’s IPO on the Swiss Exchange.
Objectives:
Gain visibility for Addex, its novel drug discovery approach and clinical programs in English language press in advance of an IPO
Method:
- Leverage two clinical milestones for one product: Phase II data from GERD and start of Phase II in migraine
- Proactively contact reporters highlighting not only data but also the innovative mechanism of action
Results:
- Significant pickup of Addex and its compound in various trade media outlets, including BioCentury, BioWorld Today, Genetic Engineering News, FDA News, Scrip, Pharma Marketletter, Pharmaceutical Business Review, R&D focus
- Major feature on migraine advances in Red Herring and Chemistry & Industry comparing Addex's product to others in development
- Introduction to reporter at BusinessWeek in Paris who subsequently wrote major article on European IPOs featuring Addex as the lead
|
